|
US2475569A
(en)
|
1944-02-07 |
1949-07-05 |
American Cyanamid Co |
Substituted pyridine compound
|
|
US4709016A
(en)
|
1982-02-01 |
1987-11-24 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
US5516931A
(en)
|
1982-02-01 |
1996-05-14 |
Northeastern University |
Release tag compounds producing ketone signal groups
|
|
US5650270A
(en)
|
1982-02-01 |
1997-07-22 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
US4650750A
(en)
|
1982-02-01 |
1987-03-17 |
Giese Roger W |
Method of chemical analysis employing molecular release tag compounds
|
|
DE60037345T2
(de)
|
1999-12-10 |
2008-11-13 |
Pfizer Products Inc., Groton |
Pyrrolo(2,3-d)pyrimidin-Verbindungen
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
DE60217322T2
(de)
|
2001-04-27 |
2007-10-04 |
Zenyaku Kogyo K.K. |
Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
PT1536827E
(pt)
|
2002-08-14 |
2009-03-20 |
Silence Therapeutics Ag |
Utilização de proteína cinase n beta
|
|
AU2004228668B2
(en)
|
2003-04-03 |
2011-10-27 |
Park Funding, Llc |
PI-3 kinase inhibitor prodrugs
|
|
ES2382377T3
(es)
|
2003-05-30 |
2012-06-07 |
Gemin X Pharmaceuticals Canada Inc. |
Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
|
|
US7129260B2
(en)
|
2003-06-02 |
2006-10-31 |
Abbott Laboratories |
Isoindolinone kinase inhibitors
|
|
EP1692153A4
(en)
|
2003-07-03 |
2007-03-21 |
Univ Pennsylvania |
INHIBITION OF EXPRESSION OF SYK-KINASE
|
|
WO2005113556A1
(en)
|
2004-05-13 |
2005-12-01 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
|
GB0419160D0
(en)
*
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
AU2006206458B2
(en)
|
2005-01-19 |
2012-10-25 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
|
KR20080011199A
(ko)
*
|
2005-04-19 |
2008-01-31 |
교와 핫꼬 고교 가부시끼가이샤 |
질소 함유 복소환 화합물
|
|
PL1888550T3
(pl)
|
2005-05-12 |
2014-12-31 |
Abbvie Bahamas Ltd |
Promotory apoptozy
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
|
US7989622B2
(en)
|
2005-10-07 |
2011-08-02 |
Exelixis, Inc. |
Phosphatidylinositol 3-kinase inhibitors and methods of their use
|
|
JP5191391B2
(ja)
|
2005-11-01 |
2013-05-08 |
ターゲジェン インコーポレーティッド |
キナーゼのビ−アリールメタ−ピリミジン阻害剤
|
|
SG10202003901UA
(en)
|
2005-12-13 |
2020-05-28 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
WO2007129161A2
(en)
|
2006-04-26 |
2007-11-15 |
F. Hoffmann-La Roche Ag |
Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
|
|
DK2526933T3
(en)
|
2006-09-22 |
2015-05-18 |
Pharmacyclics Inc |
Inhibitors of Bruton's tyrosine kinase
|
|
JPWO2008047831A1
(ja)
*
|
2006-10-17 |
2010-02-25 |
協和発酵キリン株式会社 |
Ｊａｋ阻害剤
|
|
KR101566840B1
(ko)
|
2007-03-12 |
2015-11-06 |
와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 |
페닐 아미노 피리미딘 화합물 및 이의 용도
|
|
WO2008118802A1
(en)
|
2007-03-23 |
2008-10-02 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
US8591886B2
(en)
|
2007-07-12 |
2013-11-26 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
US10047066B2
(en)
|
2007-11-30 |
2018-08-14 |
Newlink Genetics Corporation |
IDO inhibitors
|
|
GB0724342D0
(en)
|
2007-12-13 |
2008-01-30 |
Prolysis Ltd |
Anitbacterial compositions
|
|
CN103372215B
(zh)
|
2008-01-03 |
2016-03-09 |
艾克斯-马赛大学 |
抗hiv治疗期间使用的组合物和方法
|
|
HUE029767T2
(en)
|
2008-03-11 |
2017-04-28 |
Incyte Holdings Corp |
JAK inhibitor azetidine and cyclobutane derivatives
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
TW201100441A
(en)
*
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-ｇｉｔｒ 항체
|
|
EP2493862B1
(en)
|
2009-10-28 |
2016-10-05 |
Newlink Genetics Corporation |
Imidazole derivatives as ido inhibitors
|
|
ES2722300T3
(es)
|
2009-12-10 |
2019-08-09 |
Hoffmann La Roche |
Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
|
|
EP2542256B1
(en)
|
2010-03-04 |
2019-05-22 |
MacroGenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
US9169323B2
(en)
|
2010-03-05 |
2015-10-27 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R
|
|
JP5989547B2
(ja)
|
2010-03-05 |
2016-09-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトｃｓｆ−１ｒに対する抗体及びその使用
|
|
US8314120B2
(en)
|
2010-03-30 |
2012-11-20 |
Abbott Gmbh & Co. Kg |
Small molecule potentiators of metabotropic glutamate receptors
|
|
HRP20190047T1
(hr)
|
2010-05-04 |
2019-02-22 |
Five Prime Therapeutics, Inc. |
Protutijela koja se vežu na csf1r
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
NO2694640T3
(enExample)
|
2011-04-15 |
2018-03-17 |
|
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
TW201329067A
(zh)
|
2011-12-08 |
2013-07-16 |
Amgen Inc |
作為ｇｋａ活化劑之脲化合物
|
|
RU2658603C2
(ru)
|
2011-12-15 |
2018-06-21 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против человеческого csf-1r и их применения
|
|
KR20140127855A
(ko)
|
2012-02-06 |
2014-11-04 |
제넨테크, 인크. |
Csf1r 억제제를 사용하는 조성물 및 방법
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
RU2670743C9
(ru)
|
2012-05-11 |
2018-12-19 |
Файв Прайм Терапьютикс, Инк. |
Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
LT3495358T
(lt)
|
2012-11-08 |
2022-05-25 |
Bristol-Myers Squibb Company |
Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
|
|
KR102233252B1
(ko)
|
2012-11-08 |
2021-03-26 |
브리스톨-마이어스 스큅 컴퍼니 |
ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
|
|
ES2702126T3
(es)
|
2013-12-10 |
2019-02-27 |
Bristol Myers Squibb Co |
Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
|
|
WO2015131080A1
(en)
|
2014-02-28 |
2015-09-03 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
RU2017118562A
(ru)
*
|
2014-10-31 |
2018-11-30 |
Индивиор ЮКей Лимитед |
Соединения-антагонисты дофаминового d3-рецептора
|
|
WO2016101119A1
(en)
|
2014-12-23 |
2016-06-30 |
Merck Sharp & Dohme Corp. |
Fused heteroaryl derivatives as orexin receptor antagonists
|
|
KR101660863B1
(ko)
*
|
2015-04-03 |
2016-09-28 |
주식회사 녹십자 |
IKKε 및 TBK1 억제제로서의 7-아자인돌 또는 4,7-다이아자인돌 유도체 및 이를 포함하는 약학적 조성물
|
|
KR101846475B1
(ko)
*
|
2015-04-27 |
2018-04-09 |
주식회사 녹십자 |
TNIK, IKKε 및 TBK1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
|
|
MA42456B1
(fr)
|
2015-06-25 |
2021-06-30 |
Univ Health Network |
Inhibiteurs de hpk1 et leurs procédés d'utilisation
|
|
EP3402799B1
(en)
|
2016-01-15 |
2022-05-04 |
Enanta Pharmaceuticals, Inc. |
Heterocyclic compounds as rsv inhibitors
|
|
WO2017147328A1
(en)
*
|
2016-02-23 |
2017-08-31 |
Portola Pharmaceuticals, Inc. |
Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
|
US20180072741A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyrimidine compounds and uses thereof
|
|
EP3523289A1
(en)
*
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
WO2018102366A1
(en)
*
|
2016-11-30 |
2018-06-07 |
Ariad Pharmaceuticals, Inc. |
Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors
|
|
KR102314286B1
(ko)
|
2016-12-16 |
2021-10-21 |
화이자 인코포레이티드 |
Glp-1 수용체 작용제 및 이의 용도
|
|
AU2018244935A1
(en)
*
|
2017-03-30 |
2019-08-15 |
F. Hoffmann-La Roche Ag |
Naphthyridines as inhibitors of HPK1
|
|
CN109721620B
(zh)
*
|
2017-10-27 |
2022-05-13 |
药捷安康(南京)科技股份有限公司 |
Hpk1抑制剂及其用途
|
|
EP3707138B1
(en)
*
|
2017-11-06 |
2022-07-13 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
US10752635B2
(en)
*
|
2018-02-20 |
2020-08-25 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US10745388B2
(en)
*
|
2018-02-20 |
2020-08-18 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US12539292B2
(en)
|
2018-04-01 |
2026-02-03 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
KR102812426B1
(ko)
|
2018-10-29 |
2025-05-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
피리디닐 설폰아미드 유도체, 약제학적 조성물 및 이의 용도
|
|
US11142525B2
(en)
*
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
|
WO2021262684A1
(en)
|
2020-06-22 |
2021-12-30 |
Pmv Pharmaceuticals, Inc. |
METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
|